| Project description |
| Alzheimer’s disease (AD), the main cause of dementia world-wide, is clinically manifested as memory impairment and executive dysfunction. Most of the pathomechanistic studies in AD have so far largely concentrated on neurons, neglecting the role of other brain cells in neurodegeneration. The goal in the PMG-AD is to establish a personalized medicine-based approach for identification of early biomarkers and therapeutic targets in AD by focusing on novel AD-associated genetic variants in ABI3 and PLCG2 genes and consequently utilizing the latest research methodologies, human-based model systems and cohorts, and PET imaging, multilevel omics, integrative bioinformatic and endophenotype analyses to advance understanding of the role of microglia in AD. This new knowledge will advance the identification of novel candidates as personalized medicine-based biomarker and therapeutic targets for AD. |